BIOXCEL THERAPEUTICS INC.

Company Overview

Founded in 2017 and headquartered in New Haven, Conn., BioXcel Therapeutics is a clinical stage biopharmaceutical company engaged in the discovery and development of treatments for rare cancers and psychiatric disorders. The company reported net sales of $42.6 million for the financial year 2018.

BioXcel Therapeutics is creating a paradigm shift in the drug discovery for the betterment of patients. The company utilizes novel artificial intelligence for medication re-development procedures of affirmed product candidates to distinguish therapeutic indices. The company’s emerging pipeline drug includes the BXCL702 intravenous first-in-class compound that inhibits key negative regulators of pro-inflammatory cytokine receptors, one of the molecular causes for immune-cell exhaustion. Combining BXCL702 with immune checkpoint inhibition is expected to optimize T-cell antitumor activity by limiting immune-exhaustion. BXCL702 has shown direct antitumor activity against AML patient-derived cell and cell lines by inducing cell growth arrest and differentiation. BioXcel Therapeutics plans to develop BXCL in hematological malignancies with a focus on AML as mono therapy and in combination with immune-checkpoints inhibitors.

BioXcel has several drug candidates in the development pipeline. Key development products include BXCL501, BXCL701 (dipeptidyl peptidase 8/9 and fibroblast activation protein inhibitor), BXCL701 and BXCL501 (selective α2a adrenergic receptor agonist). Its clinical product candidate targeting areas include bipolar disease, schizophrenia, neuroendocrine prostate cancer, delirium, multiple tumor types and geriatric dementia.

Financial Highlights (FY 2024)

Company's Business Segments

• Product : IGALMI (dexmedetomidine), Others
• Service : Clinical Trials, AI-based Drug Re-innovation, Others